Jump to content

Drilldown: Medicines

Choose a table:


Medicines > routes: rectal & onset : LDL lowering at 2 weeks, max by 4 weeks or Symptomatic improvement 2-4 weeks

Use the filters below to narrow your results.

generic:
Mesalamine (5-aminosalicylic acid, 5-ASA) (1)
brand:
Asacol HD, Pentasa, Lialda, Apriso, Delzicol, Rowasa (rectal), Canasa (suppository) (1)
classes:
[[:Category:5-aminosalicylates|5-aminosalicylate (5-ASA)]] (1) · [[:Category:Anti-inflammatories|Anti-inflammatory]] (1) · [[:Category:IBD_medications|IBD medication]] (1)
mechanism:
None (1)
uses:
'"`UNIQ--vote-00000BBC-QINU`"', '"`UNIQ--vote-00000BBD-QINU`"' (1)
starting dose:
Active UC: Lialda 2.4-4.8 g PO once daily, Apriso 1.5 g PO once daily; maintenance 1.2-2.4 g/d; rectal Rowasa enema 4 g HS for distal disease; Canasa 1 g suppository HS for proctitis (1)
preparations:
Multiple non-bioequivalent oral formulations (pH-, time-, and moisture-dependent release); rectal enema 4 g/60 mL; 1 g rectal suppository (1)
fda max:
Formulation-specific; ~4.8 g/d typical maximum oral (1)
routes: (Click arrow to add another value)
onset: (Click arrow to add another value)
duration:
24 hours (most ER formulations) (1)
halflife:
~5-10 hours (5-ASA)'"`UNIQ--ref-00000BBE-QINU`"' (1)
bioavailability:
Highly formulation-dependent; the goal is colonic delivery with minimal systemic exposure'"`UNIQ--ref-00000BBF-QINU`"' (1)
pregnancy:
Generally considered safe at standard doses; benefits typically outweigh in active IBD.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)
legal:
[[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 1 result in range #1 to #1.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"